Very much a value stock. Not a lot of growth. You can’t too far wrong at these levels. He likes a little more growth.  

(A Top Pick May 31/17 Up 20%)  A stable, old-school pharma company.  They can still spin out some businesses and they have a lot good projects in the pipeline.  

(A Top Pick June 16/17, Up 12% ) Likes pharma and owns a couple of them. The time to buy is when they are facing a patent clift, and their biggest drugs are coming off-patents and the company has to find new drugs or buy other promising companies. Pfizer was one of those when they bought Wyeth. They have a big consumer products division, which provides lots of cash flow, good earnings but not huge growth, which they put up for sell recently but couldn’t really find a buyer. Still likes it longer term.

He's gone the biotech route in the drug sector. Over the years, he has owned the big pharmas, but their growth has stagnated with growth in earnings done through cost containment--and you can't cut forever. Topline growth is better which is where he looks first in a stock. Pfizer hasn't had this.

Teva or Pfizer?  He sold Teva 18 months ago. Generic drug prices are under pressure though have levelled off. Their migraine drug has struggled. Instead, he prefers Pfizer with 140 drugs generating $100 million in revenues. They make good acquisitions and are enjoying great progress in oncology. They're also repatriating $24.5 billion with $5 million going to buybacks. Just announced they want to sell their consumer products division, so the impact of this is unknown. 12x forward earnings. Fabulously run company. Talk of major acquisitions. Happy to hold this.

Like many of the other major pharma companies has gone through their patent cliffs. It is trading at an attractive multiple and has an attractive dividend yield. She prefers Johnson & Johnson (JNJ-O).